Sort
23,748 grants matching “melanoma”
Project 1: Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting
$343,436David E Fisher · Massachusetts General Hospital · P01 · FY2020 · CA
Programming immune function through modular assembly of polyionic immune signals
$343,426Christopher M Jewell · Univ Of Maryland, College Park · R01 · FY2020 · EB
Gamma Delta T Cell Immunotherapy of Breast Cancer
$343,392Richard D Lopez · University Of Alabama At Birmingham · P50 · FY2010 · CA
Systemic RNA interference to reactivate p53 tumor suppression
$343,370Alexander H. Stegh · Northwestern University At Chicago · R01 · FY2019 · CA
Regulation of Human Tumorigensis by Cancer Specific NXF1 Adaptor Proteins
$343,355George L Sen · University Of California, San Diego · R01 · FY2024 · CA
PHOTODYNAMIC THERAPY (PDT) AND TUMOR IMMUNITY
$343,334Sandra O Gollnick · Roswell Park Cancer Institute Corp · R01 · FY2011 · CA
IMMUNOLOGICAL APPROACHES TO BENEFIT STEM CELL REPLACEMENT THERAPY FOR DIABETES
$343,333Ashleigh Boyd · Roger Williams Hospital · P20 · FY2011 · RR
Study of Anti-Tumor Immunity and Tissue Resident Memory Cell Development by NKG2D and Ribosomal Protein S6 Signaling in T cells
$343,320Jose Alejandro Guevara-Patino · Loyola University Chicago · R01 · FY2020 · CA
Programming immune function through modular assembly of polyionic immune signals
$343,257Christopher M Jewell · Univ Of Maryland, College Park · R01 · FY2022 · EB
Site Specific Drug Delivery with Light-responsive Conjugates for Photo-biomodulation
$343,252Youngjae You · State University Of New York At Buffalo · R01 · FY2025 · GM
Site Specific Drug Delivery with Light-responsive Conjugates for Photo-biomodulation
$343,252Youngjae You · State University Of New York At Buffalo · R01 · FY2024 · GM
In vivo real time detection of circulating melanoma cells
$343,215Vladimir P Zharov · Univ Of Arkansas For Med Scis · R01 · FY2018 · CA
Project 3
$343,215Michelle Krogsgaard · New York University School Of Medicine · P50 · FY2024 · CA
Cutaneous Hemangiomas and Signal Transduction
$343,200Jack L Arbiser · Emory University · R01 · FY2014 · AR
Cutaneous Hemangiomas and Signal Transduction
$343,200Jack L Arbiser · Emory University · R01 · FY2017 · AR
Cutaneous Hemangiomas and Signal Transduction
$343,200Jack L Arbiser · Emory University · R01 · FY2015 · AR
A Phase II Trial of Riluzole in Patients with Advanced Melanoma
$343,200James S Goydos · Univ Of Med/Dent Nj-R W Johnson Med Sch · R21 · FY2009 · CA
Cutaneous Hemangiomas and Signal Transduction
$343,200Jack L Arbiser · Emory University · R01 · FY2016 · AR
A Phase II Trial of Riluzole in Patients with Advanced Melanoma
$343,200James S Goydos · Univ Of Med/Dent Nj-R W Johnson Med Sch · R21 · FY2010 · CA
Improvement of cellular immunotherapy during dysbiosis- Resubmission
$343,184Ruud P.m. Dings · Univ Of Arkansas For Med Scis · R01 · FY2023 · CA
Gamma Delta T Cell Immunotherapy of Breast Cancer
$343,144Richard D Lopez · University Of Alabama At Birmingham · P50 · FY2009 · CA
Cancer Pain: Nerve/Tumor Interactions
$343,141Alvin James Beitz · University Of Minnesota · R01 · FY2010 · CA
Function of ATF2 URE binding protein in human melanoma
$343,060Mount Sinai School Of Medicine Of Nyu · R01 · FY2001 · CA
CLASS II ANTIGEN PRESENTATION VIA CHAPERONE MEDIATED AUTOPHAGY
$343,035Janice S Blum · Indiana University Indianapolis · R01 · FY2012 · AI
CLASS II ANTIGEN PRESENTATION VIA CHAPERONE MEDIATED AUTOPHAGY
$343,035Janice S Blum · Indiana University Indianapolis · R01 · FY2011 · AI